BERWYN, PA — Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) has announced that findings from its dose range toxicity study for NES100, an innovative intranasal peptide for managing acute and chronic non-cancer pain, will be presented at The Society of Toxicology’s (SOT) 64th annual meeting and Tox Expo, taking place from March 16 to 20 in Orlando, FL.
NES100 represents a novel approach to pain management through a cutting-edge nanotechnology-based delivery system. The enkephalin drug product leverages Molecular Envelope Technology (MET) to deliver the metabolically sensitive peptide directly to the brain via the olfactory pathways, bypassing the blood-brain barrier. This unique delivery method is designed to target delta opioid receptors in the brain, offering rapid pain suppression without the risks typically associated with opioids, such as addiction, respiratory depression, or withdrawal.
“NES100 tackles long-standing challenges in pain therapy by enabling precise and non-invasive delivery of an enkephalin peptide to the brain. The potential to manage pain effectively without the drawbacks of opioids could mark a significant breakthrough in the field of pain management,” commented representatives from Virpax.
The company’s progress with NES100 is supported by an extended cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), under the National Institutes of Health (NIH). This partnership underscores Virpax’s efforts to harness advanced scientific collaboration to transform pain treatment strategies.
The upcoming presentation at SOT’s annual meeting exemplifies Virpax’s effort to advance the scientific understanding and development of its pain management candidate. NES100’s innovative features and promising findings could position it as a vital tool in addressing the opioid crisis by offering a safer alternative to traditional pain therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.